CA2717954C - Cyclopenta[g]quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia - Google Patents

Cyclopenta[g]quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia Download PDF

Info

Publication number
CA2717954C
CA2717954C CA2717954A CA2717954A CA2717954C CA 2717954 C CA2717954 C CA 2717954C CA 2717954 A CA2717954 A CA 2717954A CA 2717954 A CA2717954 A CA 2717954A CA 2717954 C CA2717954 C CA 2717954C
Authority
CA
Canada
Prior art keywords
cyclopenta
quinazoline derivative
treatment
phenylene
acute myeloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2717954A
Other languages
English (en)
French (fr)
Other versions
CA2717954A1 (en
Inventor
Gerrit Jansen
Ann Jackman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0805035A external-priority patent/GB0805035D0/en
Priority claimed from GB0805036A external-priority patent/GB0805036D0/en
Application filed by BTG International Ltd filed Critical BTG International Ltd
Publication of CA2717954A1 publication Critical patent/CA2717954A1/en
Application granted granted Critical
Publication of CA2717954C publication Critical patent/CA2717954C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2717954A 2008-03-18 2009-03-13 Cyclopenta[g]quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia Active CA2717954C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0805035A GB0805035D0 (en) 2008-03-18 2008-03-18 Us eof cyclopenta[G]quinazoline derivatives
GB0805036.1 2008-03-18
GB0805036A GB0805036D0 (en) 2008-03-18 2008-03-18 New use of cyclopenta[g]quinazoline derivatives
GB0805035.3 2008-03-18
PCT/GB2009/000687 WO2009115776A1 (en) 2008-03-18 2009-03-13 Cyclopenta[g]quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia

Publications (2)

Publication Number Publication Date
CA2717954A1 CA2717954A1 (en) 2009-09-24
CA2717954C true CA2717954C (en) 2019-06-04

Family

ID=40599662

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2717954A Active CA2717954C (en) 2008-03-18 2009-03-13 Cyclopenta[g]quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia

Country Status (10)

Country Link
US (1) US8466111B2 (cg-RX-API-DMAC7.html)
EP (1) EP2293807B1 (cg-RX-API-DMAC7.html)
JP (1) JP5599773B2 (cg-RX-API-DMAC7.html)
KR (1) KR101616022B1 (cg-RX-API-DMAC7.html)
CN (1) CN101977620B (cg-RX-API-DMAC7.html)
AT (1) ATE556715T1 (cg-RX-API-DMAC7.html)
CA (1) CA2717954C (cg-RX-API-DMAC7.html)
DK (1) DK2293807T3 (cg-RX-API-DMAC7.html)
ES (1) ES2387334T3 (cg-RX-API-DMAC7.html)
WO (1) WO2009115776A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2819510A1 (en) * 2010-12-22 2012-06-28 Onyx Pharmaceuticals, Inc. Efficient peptide couplings and their use in the synthesis and isolation of a cyclopenta(g)quinazoline trisodium salt
US20180236098A1 (en) 2016-08-12 2018-08-23 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
KR102584446B1 (ko) 2016-08-12 2023-10-04 엘.이.에이.에프. 홀딩스 그룹 엘엘씨. 알파 및 감마-d 폴리글루타메이트화 항엽산 및 이의 용도
GB201707864D0 (en) 2017-05-16 2017-06-28 Inst Of Cancer Research: Royal Cancer Hospital Platinum-reistant cancer treatment
CA3090391A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated raltitrexed and uses thereof
JP7491573B2 (ja) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化メトトレキセートおよびその使用
WO2019157146A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated antifolates and uses thereof
JP7514533B2 (ja) 2018-02-07 2024-07-11 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化テトラヒドロ葉酸およびその使用
EP3749317A4 (en) 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC PEMETREXED ALPHA-POLYGLUTAMATE AND ASSOCIATED USES
WO2019157129A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
US12246018B2 (en) 2018-02-07 2025-03-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated pemetrexed and uses thereof
US12246019B2 (en) 2018-02-07 2025-03-11 L.E.A.F. Holdings Group Llc Alpha polyglutamated lometrexol and uses thereof
CA3090384A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
WO2019157133A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
US12290518B2 (en) 2018-02-14 2025-05-06 L.E.A.F. Holdings Group Llc Gamma polyglutamated methotrexate and uses thereof
US12048767B2 (en) * 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
CA3090875A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
JP7442822B2 (ja) 2018-02-14 2024-03-05 エル．イー．エー．エフ． ホールディングス グループ エルエルシー γポリグルタミン酸化テトラヒドロ葉酸およびその使用
CA3090943A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
WO2019169029A1 (en) * 2018-02-28 2019-09-06 Bioxiness Pharmaceuticals, Inc. Target specific chemotherapeutic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223352D0 (en) 1992-11-06 1992-12-23 Ici Plc Tricyclic compounds
GB9408936D0 (en) * 1994-05-05 1994-06-22 Cancer Res Inst Anti-cancer compounds
ES2373644T3 (es) * 2001-08-31 2012-02-07 Btg International Limited Uso de derivados de ciclopenta[g]quinazolina para el tratamiento del c�?ncer.
KR100983962B1 (ko) * 2001-08-31 2010-09-27 비티지 인터내셔널 리미티드 항암제로서 사용되는 시클로펜타[ｇ]퀴나졸린 화합물
AU2003216445A1 (en) * 2002-02-27 2003-09-09 The Medical College Of Ohio Therapeutic methods for acute myeloid leukemia

Also Published As

Publication number Publication date
WO2009115776A1 (en) 2009-09-24
US20110190211A1 (en) 2011-08-04
EP2293807B1 (en) 2012-05-09
CN101977620B (zh) 2014-05-07
CA2717954A1 (en) 2009-09-24
KR20110002848A (ko) 2011-01-10
US8466111B2 (en) 2013-06-18
JP2011515384A (ja) 2011-05-19
ATE556715T1 (de) 2012-05-15
CN101977620A (zh) 2011-02-16
JP5599773B2 (ja) 2014-10-01
HK1154786A1 (en) 2012-05-04
KR101616022B1 (ko) 2016-04-28
ES2387334T3 (es) 2012-09-20
EP2293807A1 (en) 2011-03-16
DK2293807T3 (da) 2012-07-23

Similar Documents

Publication Publication Date Title
EP2293807B1 (en) Cyclopenta[g]quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia
Van Der Heijden et al. Folate receptor β as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients
JP7704815B2 (ja) Ｂｃｍａに対する結合分子及びその使用
AU2024264558A1 (en) Bicyclic peptide ligands specific for Nectin-4
KR20190067235A (ko) Vista 및 pd-1 경로의 이중 억제제
TWI686406B (zh) 結合ｔｉｍ-３之抗體分子及其用途
ES2432173T3 (es) Métodos de tratamiento de enfermedades inflamatorias crónicas usando un antagonista de GM-CSF
TW202216208A (zh) 抗體-藥物結合物及atr抑制劑之組合
KR20080099290A (ko) 암 치료용 ｉｌ-17 길항 항체
CN105143263A (zh) Bcma抗原结合蛋白
UA123090C2 (uk) 4,6-ДІАМІНОПІРИДО[3,2-d]ПІРИМІДИНОВІ СПОЛУКИ, ЯКІ МОДУЛЮЮТЬ TOLL-ПОДІБНІ РЕЦЕПТОРИ
US9914768B2 (en) Anti-S100A7 antibodies for the treatment and diagnosis of cancer
WO2014018862A1 (en) Pharmaceutical compositions comprising a heat shock protein inhibitor and a|purine de novo synthesis inhibitor for treating rheumatoid arthritis or cancer
US8940701B2 (en) Compounds for, and methods of, treating cancer and inhibiting invasion and metastases
EP3064221A1 (en) Combination therapy of anti-mif antibodies and chemotherapeutics
US20250368617A1 (en) Novel ras inhibitors
HK1154786B (en) Cyclopenta[g]quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia
NL2035852B1 (en) Enhancement of t cell mediated therapies
US20250360124A1 (en) Novel ras inhibitors
RU2812322C2 (ru) Молекулы, связывающие bcma, и пути их применения
JP6956254B2 (ja) 血管遮断剤および免疫チェックポイント阻害剤を含む癌の予防または治療用の組成物
JP2021502405A (ja) 免疫原性組成物及びその使用
EA048268B1 (ru) Молекулы, связывающие bcma, и пути их применения
AU2019407426A1 (en) Combination of antibody-drug conjugate and kinase inhibitor
HK40071709A (en) Method and composition for anti-cd73 antibodies and variants

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140313

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250912

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260226

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260226